Galecto Changes Name to Damora Therapeutics and Plans Nasdaq Listing in 2026

Galecto announced its name change to Damora Therapeutics. Effective March 10, 2026, Damora will trade on Nasdaq under the trading symbol "DMRA." The name change follows the completion of Galecto's previously announced acquisition of privately held Damora and a concurrent private investment of approximately $285M in November 2025. Combined with gross proceeds of approximately $316M from the Company's recently closed public offering in February 2026, Damora plans to rapidly advance its pipeline of mutant calreticulin-targeted therapeutics in essential thrombocythemia and myelofibrosis, beginning with lead program DMR-001. "As Damora Therapeutics, we are bringing innovative, disease-modifying medicines to patients with mutCALR-driven myeloproliferative neoplasms (MPNs), where there is high medical need and no available treatments that target the underlying cause of disease," said Sherwin Sattarzadeh, COO. "With a strong operational foundation including board and executive leadership with a track record of clinical and commercial success, we are now scaling efforts to initiate clinical development of DMR-001 and rapidly advance it toward registration." DMR-001 is an investigational monoclonal antibody therapy targeting mutCALR with best-in-class potential, demonstrated by preclinical data showing its potent inhibition of both Type 1 and Type 2 mutCALR and an extended half-life expected to enable convenient, infrequent subcutaneous dosing. The Company's additional anti-mutCALR pipeline therapies, DMR-002 and DMR-003, enable portfolio optionality to address the full spectrum of patients with mutCALR-driven MPNs.